Policy
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
Neos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided a business update.
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.
Expedeon AG reported results for the first quarter ended March 31, 2019.
Assertio Therapeutics, Inc. reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.
Epigenomics AG announced the financial results for the first quarter of the FY 2019.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
The inclusion of the list price is part of an effort from the administration to lower the cost of prescription drugs. The industry’s lobbying arm believes the inclusion will be confusing to patients.